Alfredo GarcÃ-a-Arieta

List of Publications by Year
in descending order

45 papers	641 citations	623734 14 h-index	610901 24 g-index
46 all docs	46 docs citations	46 times ranked	669 citing authors

#	Article	IF	Citations
1	In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharmaceutics and Drug Disposition, 2012, 33, 366-377.	1.9	85
2	Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: Impact on bioequivalence. European Journal of Pharmaceutical Sciences, 2014, 65, 89-97.	4.0	74
3	Investigation on the Possibility of Biowaivers for Ibuprofen. Journal of Pharmaceutical Sciences, 2011, 100, 2343-2349.	3.3	48
4	Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India. AAPS Journal, 2015, 17, 1285-1304.	4.4	47
5	Bioequivalence Requirements in the European Union: Critical Discussion. AAPS Journal, 2012, 14, 738-748.	4.4	46
6	In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. Molecular Pharmaceutics, 2018, 15, 2307-2315.	4.6	26
7	Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison. European Journal of Clinical Pharmacology, 2013, 69, 1157-1162.	1.9	22
8	Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies. European Journal of Clinical Pharmacology, 2010, 66, 599-604.	1.9	19
9	An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies. Chirality, 2005, 17, 470-475.	2.6	18
10	Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles. AAPS Journal, 2016, 18, 1550-1561.	4.4	18
11	Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120Âmg tablets as prequalified by WHO. European Journal of Clinical Pharmacology, 2012, 68, 1611-1618.	1.9	17
12	Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence. Pharmaceutics, 2019, 11, 503.	4.5	17
13	Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. Pharmaceutics, 2019, 11, 122.	4.5	17
14	Candesartan Cilexetil In Vitroâ€“In Vivo Correlation: Predictive Dissolution as a Development Tool. Pharmaceutics, 2020, 12, 633.	4.5	17
15	Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products. International Journal of Pharmaceutics, 2012, 423, 321-325.	5.2	12
16	Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets. Molecular Pharmaceutics, 2015, 12, 3194-3201.	4.6	11
17	Comparison of free software platforms for the calculation of the 90% confidence interval of f2 similarity factor by bootstrap analysis. European Journal of Pharmaceutical Sciences, 2020, 146, 105259.	4.0	11
18	High-Fat Breakfast Increases Bioavailability of Albendazole Compared to Low-Fat Breakfast: Single-Dose Study in Healthy Subjects. Frontiers in Pharmacology, 2021, 12, 664465.	3.5	11

#	Article	IF	Citations
19	Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products. Pharmaceutics, 2019, 11, 663.	4.5	10
20	A multivariate investigation into the relationship between pharmaceutical characteristics and patient preferences of bioequivalent ibuprofen tablets. Patient Preference and Adherence, 2018, Volume 12, 1927-1935.	1.8	9
21	Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. Pharmaceutics, 2021, 13, 709.	4.5	9
22	A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme. Journal of Pharmacy and Pharmaceutical Sciences, 2019, 22, 28-36.	2.1	8
23	Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms. Pharmaceutics, 2020, 12, 1159.	4.5	8
24	On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs. Journal of Pharmaceutical Sciences, 2016, 105, 1353-1354.	3.3	7
25	Global Harmonization of Comparator Products for Bioequivalence Studies. AAPS Journal, 2017, 19, 603-606.	4.4	7
26	An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics, 2021, 13, 507.	4.5	7
27	Evaluation of sexâ€byâ€formulation interaction in bioequivalence studies of efavirenz tablets. British Journal of Clinical Pharmacology, 2018, 84, 1729-1737.	2.4	6
28	On the Biopharmaceutics Classification System Biowaiver of Ibuprofen. Journal of Pharmaceutical Sciences, 2015, 104, 2429-2432.	3.3	5
29	Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons. European Journal of Clinical Pharmacology, 2015, 71, 1083-1089.	1.9	5
30	Interchangeability between First-Line Generic Antiretroviral Products Prequalified by WHO using Adjusted Indirect Comparisons. Antiviral Therapy, 2017, 22, 135-144.	1.0	5
31	Impact of Chiral Bioanalytical Methods on the Bioequivalence of Ibuprofen Products Containing Ibuprofen Lysinate and Ibuprofen Base. Chirality, 2016, 28, 429-433.	2.6	4
32	Investigation on the Existence of Sexâ€Byâ€Formulation Interaction in Bioequivalence Trials. Clinical Pharmacology and Therapeutics, 2019, 106, 1099-1112.	4.7	4
33	Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia. British Journal of Clinical Pharmacology, 2019, 85, 2059-2065.	2.4	4
34	Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications. Clinical and Translational Science, 2019, 12, 490-496.	3.1	4
35	A proposed approach for the determination of the bioequivalence acceptance range for narrow therapeutic index drugs in the European Union. Clinical Pharmacology and Therapeutics, 2021, 111, 470.	4.7	4
36	Chiral bioanalytical methods in bioequivalence studies of intravenous vs. oral formulations of ibuprofen. Chirality, 2020, 32, 1169-1177.	2.6	3

#	Article	IF	Citations
37	Estimators and confidence intervals of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.svg"><mml:msub><mml:mi>f</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math> using bootstrap methodology for the comparison of dissolution profiles. Computer Methods and Programs in Biomedicine, 2021, 212, 106449.	4.7	3
38	Reasons to use stereoselective assay methods. Chirality, 2012, 24, 499-499.	2.6	2
39	Effect of enantiomerism on the bioequivalence of a new ibuprofen 600â€mg tablet formulation obtained by roller compaction. Chirality, 2020, 32, 185-190.	2.6	2
40	A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme. Journal of Pharmacy and Pharmaceutical Sciences, 2021, 24, 113-126.	2.1	2
41	One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products. Pharmaceutics, 2021, 13, 690.	4.5	2
42	Bioequivalence assessment of inhalation products: Interchangeability, study design and statistical methods. Pulmonary Pharmacology and Therapeutics, 2010, 23, 156-158.	2.6	1
43	Establishing bioequivalence for orally inhaled drug products. Expert Opinion on Drug Delivery, 2011, 8, 1533-1534.	5.0	1
44	Sex-by-formulation interaction in bioequivalence trials with transdermal patches. European Journal of Clinical Pharmacology, 2019, 75, 801-808.	1.9	1
45	Response to â€˜Sexâ€byâ€formulation interaction in bioequivalence studies: the importance of formulations and experimental conditionsâ€™ by Ibarra et al.. British Journal of Clinical Pharmacology, 2019, 85, 857-858.	2.4	1